KDR and neoplasm: Sunitinib is a multi-kinase inhibitor with an indolinone-based planar aromatic core that targets receptor tyrosine kinases including VEGFR, PDGFR, and KIT by occupying their ATP-binding sites. This disrupts angiogenesis and tumor proliferation. In the context of oncolytic virotherapy, Sunitinib enhances viral distribution within tumors and suppresses antiviral innate immunity, thereby improving viral replication and therapeutic efficacy.